As the clinical features of tumour burden also apply to PD‐1/PD‐L1 inhibitors plus chemotherapy, it is possible that reducing the tumour burden can enhance the therapeutic effect of PD‐1/PD‐L1 inhibitors plus chemotherapy in patients with advanced NSCLC. The gene discussed is PDCD1; the disease is neoplasm.